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Abstract
The Protein C anticoagulant pathway regulates blood coagulation by preventing the inadequate formation of thrombi. It has
two main plasma components: protein C and protein S. Individuals with protein C or protein S deficiency present a
dramatically increased incidence of thromboembolic disorders. Here, we present the results of a genome-wide association
study (GWAS) for protein C and protein S plasma levels in a set of extended pedigrees from the Genetic Analysis of Idiopathic
Thrombophilia (GAIT) Project. A total number of 397 individuals from 21 families were typed for 307,984 SNPs using the
InfiniumH 317 k Beadchip (Illumina). Protein C and protein S (free, functional and total) plasma levels were determined with
biochemical assays for all participants. Association with phenotypes was investigated through variance component analysis.
After correcting for multiple testing, two SNPs for protein C plasma levels (rs867186 and rs8119351) and another two for
free protein S plasma levels (rs1413885 and rs1570868) remained significant on a genome-wide level, located in and around
the PROCR and the DNAJC6 genomic regions respectively. No SNPs were significantly associated with functional or total
protein S plasma levels, although rs1413885 from DNAJC6 showed suggestive association with the functional protein S
phenotype, possibly indicating that this locus plays an important role in protein S metabolism. Our results provide evidence
that PROCR and DNAJC6 might play a role in protein C and free protein S plasma levels in the population studied, warranting
further investigation on the role of these loci in the etiology of venous thromboembolism and other thrombotic diseases.
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Introduction
The protein C anticoagulant pathway is an important physiological
mechanism that regulates blood coagulation. It prevents the
inadequate formation of thrombi and has two main plasma
components: protein C and protein S.
Protein C (PC) is a vitamin K-dependent serine protease, which
acts as an anticoagulant by inactivating activated Factors V (FVa)
and VIII (FVIIIa). PC is activated by the thrombin/thrombomo-
dulin complex on the surface of endothelial cells, where it binds
with endothelial PC receptor (EPCR) [1,2]. EPCR also circulates
in a soluble form (sEPCR) with similar affinity to both PC and
activated PC (APC). Moreover, sEPCR acts as an inhibitor of APC
[3].
Protein S (PS) is also a vitamin K-dependent anticoagulant
plasma protein. It has no enzymatic activity, but acts as a cofactor
to activated PC in the inactivation of FVa and FVIIIa. Moreover,
PS is a cofactor for tissue factor pathway inhibitor (TFPI) for
inhibiting FXa [4]. PS circulates either as a free molecule (fPS;
,40% of the total PS) or as a complex with the C4b-binding
protein (C4BP-PS; ,60% of the total PS) [5]. Until recently, it was
thought that only fPS had cofactor activity; however, now there is
growing evidence that the C4BP-PS complex participates directly
in FVa and FVIIIa inactivation [6].
Individuals with PC or PS deficiency present a dramatically
increased incidence of thromboembolic disorders [7]. Many of the
mutations that cause these deficiencies are located in and around
the structural genes of PC and PS (PROC and PROS1 respectively)
[8–10]. However, a high proportion of families with PC or PS
deficiency have no mutations in these genes [11]. Moreover,
several polymorphisms in the promoter of the PROC gene account
for a mere ,6% of the quantitative variation of PC levels [12].
These observations suggest that the genetic mechanisms underly-
ing PC and PS plasma levels are still largely unknown and that
more loci, other than the two structural genes, are involved in the
variability of these traits.
A genome-wide linkage analysis using the data from the family-
based GAIT Project was performed to find novel loci affecting PC
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variation in the PROC and PROS1 genomic regions is not a
primary determinant of the quantitative variation of PC and PS
plasma levels. Rather, PC levels showed significant linkage with
chromosomal region 16q23. This region contains a candidate
gene, NQO1 coding for NAD(P)H:dehydrogenase quinone 1,
involved in vitamin K metabolism [13]. In addition, there was
strong evidence of linkage between chromosomal region 1q32 and
fPS plasma levels. Interestingly, this region contains the genes that
code for the a and b chains of the C4b-binding protein (C4BPA
and C4BPB) [14]. Moreover, using a tagSNP approach, the
Cardiovascular Health Study (CHS) reported that polymorphism
rs867186 from the gene that codes for EPCR (PROCR) was
associated with higher levels of circulating PC antigen and that
polymorphism rs1878672 from the IL10 gene was associated with
higher fPS levels [15].
More recently, a genome-wide association scan for loci affecting
PC plasma levels in a large sample of patients and controls of
European descent identified three novel loci (GCKR, EDEM2 and
BAZ1B), together with two already known (PROC and PROCR)
[16]. In addition, a genome-wide linkage analysis reported that a
quantitative trait locus in chromosomal region 20q11 (including
genes FOXA2, THBD and PROCR) influences PC levels in one
extended family from the GENES study [17,18]. A subsequent
study revealed that PROCR haplotype 3 and a SNP from FOXA2
(rs1055080) were associated with PC levels in this family, but only
PROCR haplotype 3 was associated also with plasma levels in
healthy individuals [19].
The top (i.e., showing the most significant associations) SNPs
from the five genes found in the aforementioned genome-wide
association scan explained only a fraction (28.2%) of the variance
in PC plasma levels [16]. Since previous studies postulated that
,50% of the phenotypic variation in PC plasma levels is caused by
the additive effect of genes [20] the discovery of more loci is
tenable. Bearing this in mind, we carried out the first GWAS that
encompasses the two main components of the protein C anticoagulant
pathway (PC and functional, free and total PS levels). The objective
of this work was to search for SNPs that influence PC and PS
plasma levels and potentially increase the risk of venous
thrombosis. We were successful in identifying such loci.
Methods
Ethics Statement
The Institutional Review Board of the Hospital de la Santa
Creu i Sant Pau approved all protocols used in the GAIT Project
and participants gave their informed consent, in compliance with
the Declaration of Helsinki.
The GAIT Project: a brief description
The GAIT Project included 397 individuals from 21 extended
Spanish families (mean pedigree size=19) [20–21]. Twelve of
these families were selected on the basis of a proband with
idiopathic thrombophilia, whereas the remaining nine families
were selected randomly. Age ranged from ,1 to 88 years
(mean=37.7) and male to female sex ratio was 0.85.
Plasma measurements
PC plasma concentrations were measured by a biochemical
analyzer (CPA Coulter, Coulter Corp) using chromogenic
methods from Chromogenix. Functional PS (funcPS) was assayed
with the STA automated coagulometer (Boehringer Mannheim)
and determined with a Diagnostica Stago kit. fPS and total protein
S (free+C4b–bound) were assayed with an ELISA-based commer-
cial kit (Diagnostica Stago). To reduce experimental error, each
assay was performed twice and the average value was calculated
for each participant. Intra- and inter-assay coefficients of variation
were between 2% and 6%.
Genotypic determinations and data cleaning
A genome-wide set of 307,984 SNPs was typed in all of the
participants using the InfiniumH 317 k Beadchip on the Illumina
platform (San Diego, CA, USA). Genotype imputation was
performed with Merlin [22] to avoid missing values and all
genotypes were checked for Mendelian inconsistencies. In
addition, any SNP with call rate,95%, MAF,0.025 or failing
to fit Hardy-Weinberg proportions taking into account multiple
testing (p,5610
27) was removed from the study. In total, 24,547
SNPs failed to pass the data cleaning criteria, leaving a set of
283,437 SNPs for further analysis.
Statistical analysis
Association with phenotypes was investigated through variance
component analysis that takes into account the family relationships
among individuals. The quantitative phenotype (y) was modeled as
a linear function of the genetic effect of a SNP (snp), the polygenic
effect (g) and a random environmental deviation (e):
y~mzbisnpizgze
The covariance among phenotypic values (V) was modeled using
the kinship coefficient matrix (W) derived from the family
structure:
V~2Ws2
gzIs2
e
whereby s2
g and s2
e are the variances of the polygenic and
environmental effects and I is the identity matrix.
The analysis was performed with the SOLAR v4.0 statistical
package [23]. Variance component methods present considerable
advantages when combined with extended families for the
localization of QTLs, as it is now clear that large complex
pedigrees have substantially more power per sampled individual
than smaller families do [24–26]. All plasma phenotypes (PC fPS,
funcPS and total PS) were log-transformed and adjusted for age
and sex. Measured genotype analysis was used for testing
association, assuming an additive genetic model [27]. Finally,
the Benjamini – Hochberg (B-H) adjustment [28] was applied to
the p-values using the p.adjust function in R and assuming a 10%
false discovery rate.
Results
PC, fPS, funcPS and total PS plasma levels in the GAIT sample
have been comprehensively described elsewhere [13,14]. In brief,
PC plasma levels ranged from 37% to 198% those of healthy
donors, with a mean value of 118.3% (standard deviation=19.5%)
adjusted for age and gender. In addition, fPS plasma levels ranged
from 54% to 166% those of healthy donors and the mean age-
adjusted fPS value was 109.4% for men (standard devia-
tion=21.3%) and 89.2% for women (standard deviation=18.0%).
Finally, mean funcPS and total PS plasma levels were 96.5%
(range: 30%–188%; standard deviation=21.7%) and 101.5%
(range: 60%–176%; standard deviation=20.7%) those of healthy
donors respectively.
GWAS of the Protein C Anticoagulant Pathway
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phenotypes (PC, funcPS, fPS and total PS plasma levels). In all
plasma phenotypes, association statistics followed the expected x
2
distribution under the null hypothesis of no association (Figure 1).
From the 283,437 SNPs that were tested, two SNPs for the PC
plasma levels (rs867186 and rs8119351) and another two for the
fPS plasma levels (rs1413885 and rs1570868) remained significant
on a genome-wide level, after applying the B-H adjustment.
Polymorphism rs867186 is located in the PROCR gene and is
responsible for a non-synonymous substitution in the amino acid
chain of EPCR (S219G), whereas polymorphism rs8119351 is
intergenic, located at ,10 Kbp upstream from rs867186, with
no apparent function. Each copy of minor allele from rs867186
(G) and rs8119351 (A) seems to increase PC plasma levels by
0.845 and 0.812 standard deviations and to explain 10.27% and
9.56% of the variance in PC plasma levels respectively (Table 2).
Table 1. Top ten SNP associations for PC, fPS, funcPS and total PS plasma levels.
Phenotype SNP Location x
2 p-values Gene
PC rs867186 Chr20:33228215 34.69 3.87610
209* PROCR
PC rs8119351 Chr20:33218066 30.24 3.81610
208* PROCR
PC rs11906160 Chr20:33029416 23.26 1.41610
206 MYH7B
PC rs13230047 Chr7:36927845 19.93 8.02610
206 ELMO1
PC rs1006973 Chr14:51146839 19.86 8.33610
206 FRMD6
PC rs6060239 Chr20:33158241 18.74 1.50610
205 C20orf31
PC rs6691481 Chr1:19216466 18.67 1.56610
205 RBAF600
PC rs884608 Chr9:36490359 18.60 1.61610
205 MELK
PC rs915664 Chr6:30902596 18.46 1.74610
205 DDR1
PC rs780873 Chr12:114680164 18.35 1.84610
205 THRAP2
fPS rs1413885 Chr1:65588247 26.02 3.37610
207* DNAJC6
fPS rs1570868 Chr1:65603196 25.72 3.94610
207* DNAJC6
fPS rs12086738 Chr1:65580000 22.10 2.58610
206 DNAJC6
fPS rs2137111 Chr15:75638590 20.07 7.48610
206 LRRN6A
fPS rs2439430 Chr15:64704898 18.83 1.43610
205 LCTL
fPS rs7983232 Chr13:21635599 18.50 1.70610
205 FGF9
fPS rs10489924 Chr1:99231562 18.43 1.76610
205 PAP2
fPS rs2375699 Chr1:65580869 18.34 1.85610
205 DNAJC6
fPS rs1878449 Chr4:155107054 17.39 3.04610
205 SFRP2
fPS rs4295666 Chr8:22618037 17.11 3.53610
205 PEBP4
funcPS rs13130255 Chr4:43232357 21.63 3.31610
206 KCTD8
funcPS rs3829183 Chr10:70793644 19.41 1.06610
205 HK1
funcPS rs1013719 Chr7:10521275 19.24 1.15610
205 NDUFA4
funcPS rs1106523 Chr2:241900212 18.73 1.50610
205 SEPT2
funcPS rs6724257 Chr2:241871070 18.73 1.50610
205 HDLBP
funcPS rs425459 Chr17:47409200 18.55 1.66610
205 CA10
funcPS rs2712001 Chr4:38823444 18.01 2.20610
205 KLHL5
funcPS rs763773 Chr6:144434079 17.99 2.22610
205 SF3B5
funcPS rs6921460 Chr6:144439852 17.90 2.33610
205 SF3B5
funcPS rs1413885 Chr1:65588247 17.53 2.82610
205 DNAJC6
Total PS rs1401543 Chr3:137070501 19.88 8.23610
206 PPP2R3A
Total PS rs1607504 Chr3:137076926 19.88 8.23610
206 PPP2R3A
Total PS rs2523674 Chr6:31544768 19.60 9.53610
206 HCP5
Total PS rs7648592 Chr3:137057769 19.36 1.08610
205 PPP2R3A
Total PS rs6762218 Chr3:137064983 18.20 1.99610
205 PPP2R3A
Total PS rs7029526 Chr9:119162623 18.13 2.06610
205 ASTN2
Total PS rs7095665 Chr10:87294479 17.96 2.25610
205 GRID1
Total PS rs1372328 Chr9:118524349 17.53 2.82610
205 ASTN2
Total PS rs2723603 Chr11:133174597 17.32 3.16610
205 SPATA19
Total PS rs10241576 Chr7:37825948 16.90 3.93610
205 TXNDC3
An asterisk in the p-value indicates significance after B-H adjustment for multiple comparisons.
doi:10.1371/journal.pone.0029168.t001
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SNPs belong to the same LD block (D9=0.99; r
2=0.91;
p=6.74610
215). On the other hand, both significant SNPs for
the fPS plasma levels (rs1413885 and rs1570868) are intronic,
located in the DNAJC6 gene, and have no known function. In
this case, each copy of minor allele from rs1413885 (C) and
rs1570868 (T) seems to increase fPS plasma levels by 0.428 and
0.415 standard deviations and to explain 6.24% and 7.53% of
the variance in fPS plasma levels respectively (Table 2). Again,
these observations are not completely independent as the
two SNPs present significant LD (D9=0.78; r
2=0.44;
p=1.36610
214). It is also important to note that two more
SNPs from the DNAJC6 genomic region (rs12086738 and
rs2375699) also showed suggestive association with fPS plasma
levels (Table 1).
Although none of the SNPs were significantly associated with
funcPS or total PS plasma levels (Table 1), one of the significant
SNPs for fPS (rs1413885) also ranked among the top hits for
funcPS (p=2.82610
205), suggesting that DNAJC6 might be
involved in the PS metabolism. Finally, it is also worth noting
that four out of five top hits for total PS levels were from the same
genomic region (PPP2R3A). Although none of these SNPs rose to
genome-wide significance levels (p-values between 10
206 and
10
205) they deserve special attention.
Figure 1. Quantile-quantile plots of theoretical (x-axis) vs. experimental (y-axis) x
2 statistics. Each plot represents one of the four plasma
phenotypes (PC, fPS, funcPS and total PS). The red lines (y=x) correspond to equal theoretical and experimental distributions.
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The aim of this study was to shed more light on the genetic
mechanisms underlying the protein C anticoagulant pathway through a
GWAS of the plasma levels of PC, fPS, funcPS and total PS; these
levels are strongly involved in the development of thromboembolic
disorders.
We were able to detect associations between two tightly linked
SNPs from the PROCR genomic region (coding for EPCR) and PC
plasma levels, also found in previous studies [15,16,18,19]. In this
respect, these particular results of ours stand as an independent
replication from a family-based perspective. EPCR is an
endothelial cell-specific transmembrane protein that is involved
in the protein C anticoagulant pathway by enhancing the activation rate
of PC [29,30]. Increased levels of sEPCR have been associated
with an increased risk of thrombotic events [31,32]. From the two
most significant SNPs we found in the PROCR gene, rs867186 is
more likely to play a causative role in determining the PC plasma
levels, as it is located in exon 4 of the PROCR gene and leads to an
amino acid change (S219G). More importantly, previous studies
have associated S219G with increased risk of venous thrombo-
embolism [33,34]; moreover, a haplotype including S219G has
been associated with increased risk of venous thromboembolism in
carriers of (i) Factor V Leiden [35]; (ii) the G20210A mutation in
the prothrombin gene [36]; and (iii) other dysfunctional PC
variants [32]. It has been proposed that S219G either affects the
binding properties of sEPCR or enhances its secretion from the
endothelial surface leading to alterations of circulating PC [15].
In addition, we were able also to detect significant associations
between two SNPs from a novel candidate gene (DNAJC6) and fPS
plasma levels, as well as suggestive associations between another
two SNPs from DNAJC6 and the same trait. Interestingly, the most
significant SNP for fPS plasma levels (rs1413885) also showed
suggestive association with funcPS, underpinning the involvement
of DNAJC6 in different PS traits. The exact function of DNAJC6 is
still unknown; according to the UniProt database (http://www.
uniprot.org) the protein coded by DNAJC6 resembles a tyrosine-
protein phosphatase auxilin, an enzyme promoting the uncoating
of clathrin-coated vesicles, thus playing a possible role in
endocytosis. Endocytosis itself, followed by partial proteolysis, is
involved in coagulation, through the molecular modification of FV
and FVIII: partially proteolyzed FV exhibits significant procoag-
ulant activity and resistance to activated PC [37]. Thus, a similar
mechanism involving DNAJC6 and fPS is possible, although the
validation of this hypothesis would require further investigation.
Even though we were successful in discovering a novel locus for
fPS plasma levels (DNAJC6) and replicating previous data on PC
plasma levels, we did not find any significant associations for
funcPS and total PS plasma levels. An ad hoc query of the STRING
database (http://string.embl.de) for pathways of possible biological
relevance involving the top hits from each PS phenotype (as listed
in Table 1) gave no evidence of protein–protein interactions.
In a previous linkage study based on the GAIT sample, we
reported NQO1 as a candidate gene affecting variation in PC
plasma levels [13]. Further analysis showed that one intronic SNP
(rs1437135) from NQO1 was significantly associated with PC
plasma levels [13]. Unfortunately, this SNP was not present in the
Illumina chip that we used for our genome-wide association
analysis, so no direct comparisons could be made. Nevertheless,
another SNP from the NQO1 genomic region (rs1800566) was
included in the Illumina chip. Although this SNP is in full LD with
rs1437135, it did not show significant association with PC plasma
levels on a genome-wide level (p=0.061). Moreover, we have
reported strong evidence of linkage between chromosomal region
1q32 and fPS plasma levels; interestingly, this region contains two
genes of high biological relevance, C4BPA and C4BPB, coding for
the principal binding protein of PS [14]. However, our genome-
wide association study found no association between these two
genes and any of the PS phenotypes on a genome-wide level.
This is the first time we have evidence that the PROCR gene is
associated with PC plasma levels in the GAIT sample, as the
linkage study performed previously [13] did not identify any
linkage between the PROCR genomic region and this phenotype
[logarithm of the odds (LOD) score=0.670]. In a similar manner,
no linkage was previously found between the DNAJC6 genomic
region and fPS plasma levels (LOD score=0.089) [14]. Several
issues arise from this apparent lack of concordance between
genome-wide association and genome-wide linkage studies from
the GAIT Project. It is important to note that GAIT is one of the
few projects that allow us to perform this comparison.
From the methodological point of view, linkage differs from
association in that it is based on the joint transmission of a marker
and a functional site from parent to offspring (i.e. co-segregation),
rather than on correlation due to LD. In this context, the
association approach has difficulty in detecting rare variants
through LD with common SNP markers, but such variants can be
found by linkage. Thus, an explanation for the failure to detect the
same loci in our analysis might be that linkage signals in GAIT
might be due to rare variants at those loci, whereas association
might be due to more common variants. This observation does not
rule out the presence of other variants at those loci with small
effect on PC or PS levels and our study does not have enough
power to detect such small effects. It is important to note that if we
cannot detect the effect of the other QTLs because it is small, this
emphasizes our results that PROCR and DNAJC6 are major
determinants of PC and PS levels in the Spanish population.
Taken together, the linkage and association analyses we carried
out in the context of the GAIT Project are a good example of how
rare and common variants underlying the genetic architecture of
complex traits, such as PC and PS plasma levels. In addition, it is
important to emphasize that no single method or model for
studying genetic architecture can be adopted universally. No single
method can answer all or even some of the questions without being
used in concert with additional approaches.
In summary, our work provides evidence that the PROCR and
DNAJC6 loci are involved in the genetic determination of the PC
and fPS plasma levels respectively. However, these observations
Table 2. Summary of the four statistically significant SNPs on
a genome-wide level.
rs867186 rs8119351 rs1413885 rs1570868
Position 20q11.22 20q11.22 1p31.3 1p31.3
Genomic region PROCR PROCR DNAJC6 DNAJC6
Function Missense Intergenic Intronic Intronic
Alleles (major/minor) A/G G/A T/C C/T
MAF
(1) 0.077 0.074 0.322 0.391
b
(2) 0.845 0.812 0.428 0.415
R
2(3) 10.27 9.56 6.24 7.53
LD estimates were based on founders alone.
(1)MAF: minor allele frequency based only on founders;
(2)b: effect size on PC (for rs867186 and rs8119351) and PS (for rs1413885 and
rs1570868) plasma levels per minor allele (standard deviation scale);
(3)R
2: proportion of variance explained by each SNP assuming lack of LD.
doi:10.1371/journal.pone.0029168.t002
GWAS of the Protein C Anticoagulant Pathway
PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e29168should be further validated by means of functional experiments,
especially for the fPS plasma levels, as the function of the DNAJC6
gene is still unknown.
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